quarta-feira, 7 de outubro de 2026
PesquisarExplore
Via News Knowledge File

Bank of America

organization80% conf.·synced Oct 7, 2026

Investment bank providing analyst coverage of Netflix

60
sourced metrics
864
relationships
20
stated objectives
7
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Market Cap
378237759063USD
Oct 6, 2026reference only
Price 52 Week Low
46.72USD
Oct 6, 2026reference only
Stock Price
54.09USD
Oct 6, 2026reference only
Stock Return Ytd
-3.3%
Oct 6, 2026reference only
Price 52 Week High
64.81USD
Oct 6, 2026reference only
Shares Outstanding
6992748365.0shares
Jul 30, 2026reference only
Total Liabilities
3198097000000.0USD
Jun 30, 2026reference only
Stockholders Equity
301094000000.0USD
Jun 30, 2026reference only
Eps
1.21USD_per_share
Jun 30, 2026reference only
Revenue
31558000000.0USD
Jun 30, 2026reference only
Total Assets
3499191000000.0USD
Jun 30, 2026reference only
Net Income
9074000000.0USD
Jun 30, 2026reference only
Operating Cash Flow
41770000000.0USD
Mar 31, 2026reference only

Stated objectives

Approve modest crypto allocations for private wealth clients

source
by 2026-01-01 00:00:00stated

Net interest income growth target for 2026

source
target: 5-7% growth by 2026-12-31 00:00:00stated

Maintain operating leverage by growing revenue faster than expenses

source
target: positive operating leverage by 2026-12-31 00:00:00stated

Tech stocks expected to see record $75 billion inflow in 2025

source
target: 75_billion_USD by 2025-12-31 00:00:00stated

S&P 500 price target of 7,100 by end of 2026

source
target: 7100 by 2026-12-31 00:00:00stated

Maintain control over AI governance through proprietary platform development and patent filings as AI systems move toward autonomy

source
stated

Blue Owl price target of $24

source
target: 24 stated

Blue Owl stock to reach $24 price target

source
target: 24 USD stated

NII growth of 5-7% year-over-year

source
target: 5-7% by 2026-01-01 00:00:00stated

Loans and deposits CAGR over medium term

source
target: 5% loans, 4% deposits stated

Relationship graph · 864 connections

Covered by
336
Employs
200
rates
75
Competes with
59
Invested in
26
subsidiary of
22
Developed by
19
Customer of
16

Via News coverage

This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com